FDA 483 - Jiangsu Tianhe Pharmaceutical Co. - February 28, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Jiangsu Tianhe Pharmaceutical Co. in Yangzhou, China, received a Form FDA 483 with five observations during an inspection from February 24-28, 2025. The inspection revealed significant deficiencies in manufacturing process validation, equipment qualification, alarm management, stability sampling plans, analytical method validation, and overall quality unit oversight, including data integrity issues. Several observations were repeats from a previous inspection, indicating persistent compliance problems.
ID · ee6b5e81-f06d-4112-b58a-02c4d8dd56ad